SafeNET: Initial development and validation of a real-time tool for predicting mortality risk at the time of hospital transfer to a higher level of care

por Altieri Dunn, Stefanie C., Bellon, Johanna E., Bilderback, Andrew, Borrebach, Jeffrey D., Hodges, Jacob C., Wisniewski, Mary Kay, Harinstein, Matthew E., Minnier, Tamra E., Nelson, Joel B., Hall, Daniel E.
Publicado 2021

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

por Bariola, J Ryan, McCreary, Erin K, Wadas, Richard J, Kip, Kevin E, Marroquin, Oscar C, Minnier, Tami, Koscumb, Stephen, Collins, Kevin, Schmidhofer, Mark, Shovel, Judith A, Wisniewski, Mary Kay, Sullivan, Colleen, Yealy, Donald M, Nace, David A, Huang, David T, Haidar, Ghady, Khadem, Tina, Linstrum, Kelsey, Seymour, Christopher W, Montgomery, Stephanie K, Angus, Derek C, Snyder, Graham M
Publicado 2021

Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days

por McCreary, Erin K., Bariola, J. Ryan, Minnier, Tami, Wadas, Richard J., Shovel, Judith A., Albin, Debbie, Marroquin, Oscar C., Schmidhofer, Mark, Wisniewski, Mary Kay, Nace, David A., Sullivan, Colleen, Axe, Meredith, Meyers, Russell, Khadem, Tina, Garrard, William, Collins, Kevin, Wells, Alan, Bart, Robert D., Linstrum, Kelsey, Montgomery, Stephanie K., Haidar, Ghady, Snyder, Graham M., McVerry, Bryan J., Seymour, Christopher W., Yealy, Donald M., Huang, David T., Angus, Derek C.
Publicado 2022

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19

por McCreary, Erin K., Bariola, J. Ryan, Wadas, Richard J., Shovel, Judith A., Wisniewski, Mary Kay, Adam, Michelle, Albin, Debbie, Minnier, Tami, Schmidhofer, Mark, Meyers, Russell, Marroquin, Oscar C., Collins, Kevin, Garrard, William, Berry, Lindsay R., Berry, Scott, Crawford, Amy M., McGlothlin, Anna, Linstrum, Kelsey, Nakayama, Anna, Montgomery, Stephanie K., Snyder, Graham M., Yealy, Donald M., Angus, Derek C., Kip, Paula L., Seymour, Christopher W., Huang, David T., Kip, Kevin E.
Publicado 2022

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label,...

por Huang, David T., McCreary, Erin K., Bariola, J. Ryan, Wadas, Richard J., Kip, Kevin E., Marroquin, Oscar C., Koscumb, Stephen, Collins, Kevin, Shovel, Judith A., Schmidhofer, Mark, Wisniewski, Mary Kay, Sullivan, Colleen, Yealy, Donald M., Axe, Meredith, Nace, David A., Haidar, Ghady, Khadem, Tina, Linstrum, Kelsey, Snyder, Graham M., Seymour, Christopher W., Montgomery, Stephanie K., McVerry, Bryan J., Berry, Lindsay, Berry, Scott, Meyers, Russell, Weissman, Alexandra, Peck-Palmer, Octavia M., Wells, Alan, Bart, Robert, Albin, Debbie L., Minnier, Tami, Angus, Derek C.
Publicado 2021

The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial

por McCreary, Erin K., Bariola, J. Ryan, Minnier, Tami E., Wadas, Richard J., Shovel, Judith A., Albin, Debbie, Marroquin, Oscar C., Kip, Kevin E., Collins, Kevin, Schmidhofer, Mark, Wisniewski, Mary Kay, Nace, David A., Sullivan, Colleen, Axe, Meredith, Meyers, Russell, Weissman, Alexandra, Garrard, William, Peck-Palmer, Octavia M., Wells, Alan, Bart, Robert D., Yang, Anne, Berry, Lindsay R., Berry, Scott, Crawford, Amy M., McGlothlin, Anna, Khadem, Tina, Linstrum, Kelsey, Montgomery, Stephanie K., Ricketts, Daniel, Kennedy, Jason N., Pidro, Caroline J., Haidar, Ghady, Snyder, Graham M., McVerry, Bryan J., Yealy, Donald M., Angus, Derek C., Nakayama, Anna, Zapf, Rachel L., Kip, Paula L., Seymour, Christopher W., Huang, David T.
Publicado 2022